news
European Commission approves first treatment for peanut allergy
Aimmune Therapeutics' PALFORZIA® has been approved by the European Commission as a treatment for peanut allergy.
List view / Grid view
Palforzia
news
EMA recommends 10 medicines for approval in October meeting
Ten medicines have been recommended for marketing authorisation and 10 extensions of indication have been suggested by the EMA.
news
Nestlé Health Science to acquire Aimmune Therapeutics for $2.6 billion
Nestlé Health Science will acquire Aimmune Therapeutics for a total value of $2.6 billion, extending the former's food allergy portfolio.
news
FDA approves Palforzia for treatment of peanut allergy in children
Palforzia, a peanut allergen powder, has been approved for the reduction of allergic reactions in children aged four to 17. It is not an emergency treatment but instead designed to build tolerance.
